Funder: National Institutes of Health

Due Dates: June 11, 2025 (New) | July 11, 2025 (Renewal/Resubmission/Revision) | October 15, 2025 (New/Renewal/Resubmission/Revision) | February 13, 2026 (New/Renewal/Resubmission/Revision) | June 10, 2026 (New) | July 10, 2026 (Renewal/Resubmission/Revision) | October 14, 2026 (New/Renewal/Resubmission/Revision)

Funding Amounts: Up to $250,000 direct costs per year, for a maximum of 3 years (UH3 mechanism, cooperative agreement).

Summary: Supports clinical validation of analytically validated assays for high-quality cancer biomarkers to enable their integration into clinical studies, excluding early-stage technology development and clinical trials.

Key Information: Clinical trials are not allowed; only applications with analytically validated assays are eligible.